Blood viscosity in patients with diffuse large B cell non-Hodgkin’s lymphoma
The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin’s lymphoma (NHL). Methods: The viscosity of blood samples from 20 patients with newly diagnosed aggressive NHL (stage I, n = 7; stage II, n = 4; stage III, n =...
Збережено в:
Дата: | 2006 |
---|---|
Автори: | , , , , , , , , |
Формат: | Стаття |
Мова: | English |
Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2006
|
Назва видання: | Experimental Oncology |
Теми: | |
Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/137926 |
Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
Цитувати: | Blood viscosity in patients with diffuse large B cell non-Hodgkin’s lymphoma / G. Utkan, I. Tek, M. Kocer, S. Muallaoglu, A.G. Durnalı, U.Y. Arslan, G. Celenkoglu, S. Tokluoglu, N. Alkis // Experimental Oncology. — 2006. — Т. 28, № 4. — С. 326-327. — Бібліогр.: 9 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of UkraineРезюме: | The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin’s lymphoma (NHL). Methods: The viscosity of blood samples from 20 patients with newly diagnosed aggressive NHL (stage I, n = 7; stage II, n = 4; stage III, n = 7; stage IV, n = 2) was analyzed using Brookfield DV-II + (USA) machine. Results: Blood viscosity in NHL patients (median: 5.5 ± 1.46 miliPascal) inversely correlated with lactatdehydrogenase (LDH) level, international prognostic index (IPI) score, and stage (p = 0.02, r= –0.51; p = 0.03, r= –0.63; and p = 0.04, r= –0.45, respectively) and positively correlated with hemoglobin level (p = 0.02, r = 0.65)). Conclusion: According to our data, blood viscosity may be considered as a follow up marker in NHL patients along with LDH level or sedimentation rate. |
---|